Draft:Matt Cooper (scientist)

Matt Cooper is an Australian scientist and researcher focused on platform technologies, clinical diagnostics, therapeutics for inflammatory, autoimmune, and infectious diseases.

Education
Cooper completed his BSc and PhD in Organic chemistry in 1995 at the University of Adelaide, Australia. He then worked at the University of Cambridge, where he worked on biosensors and molecular recognition.

Career
He has focused on interactions of ligands with membrane receptors.

He returned to Australia with a National Health and Medical Research Council (NHMRC) Australia Fellowship at the University of Queensland, where he founded the Center for Superbug Solutions, Community for Open Access Antibiotic Discovery (CO-ADD), and Center for Drug Discovery and Design.

He is the founder of Sitala, a biotech company focused on blocking harmful inflammation linked to Parkinson's disease. Along with Luke O'Neill, he co-founded Inflazome, which was sold to Roche in September 2020 for AUS$620 million.